Abstract
Stroke accounts for about 20% of deaths in diabetes patients. Not much is known about the underlying triggers for stroke in this population, but fibrinogen plasma levels have been shown to be a potential risk factor for stroke in diabetes patients. In diabetes, fibrinogen undergoes non-enzymatic glycation in the presence of uncontrolled blood glucose levels. Furthermore, a significant association has been found between blood glucose and γ’ fibrinogen. Both glycated and γ’ fibrinogen can alter fibrin structure and function. In the present study we will investigate how these fibrinogen variants interact with leukocytes and contribute to stroke in type 2 diabetes patients. The fibrinogen-leukocyte interaction will be investigated using commercially available fibrinogen variants and isolated leukocytes from type 2 diabetes patients and healthy controls. The level of glycated and γ’ fibrinogen will be determined in plasma of type 2 diabetes patients with no comorbidities. These are patients enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes with follow-up on stroke. Diabetes patients with stroke (n=200) will be compared with a control group of 200 diabetes patients without stroke. Finally, we will measure fibrin clot characteristics such as fibrin polymerization and fibrinolysis in the same plasma samples.
Formål
To investigate how fibrinogen variants interact with leucocytes and contribute to stroke in type 2 diabetes patients.
Studiepopulation
Patients with diabetes, but no comorbidities, will be included in this study. These are patients enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort.
Artikler
Finansiering
SDCO PhD-grant
Region Syddanmark
SDU fakultetsstipendium/ekstern funding
Regionens Forskningspulje 2
DD2 er ledet af Steno Diabetes Centrene
